Please login to order a test.
Evaluate toxicity; monitor therapeutic levels
Liquid chromatography/tandem mass spectrometry (LC/MS-MS)
Therapeutic: 30−300 ng/mL
The drug is used in the management of psychotic disorders, control of nausea, preventing apprehension before surgery, acute porphyria, treatment of tetanus, and intractable hiccups. Although intestinal absorption is complete, the oral bioavailability is 32%±19% because of variable metabolism in the intestinal wall and liver (marked first-pass effect). Time to peak plasma concentration is two to four hours. After intramuscular administration, peak plasma concentrations are 4 to 10 times higher than after oral administration; onset of action occurs within 20 to 30 minutes, and the peak levels are noted in two to three hours. Volume of distribution (21±9 L/kg) is high and plasma binding (95% to 98%) is extensive. Clearance after intramuscular administration is 8.6±2.9 mL/minute/kg. Less than 1% of the drug is excreted unchanged by the kidney. The nominal elimination plasma half-life is 30±7 hours; however, some metabolites are eliminated slowly (months) in the urine. Hepatic enzyme induction with increased clearance usually is a minor effect that varies considerably among individuals.
At least 100 metabolites of chlorpromazine appear in humans; most are minor. Several, including 7-hydroxychlorpromazine, 11-hydroxychlorpromazine, norchlorpromazine, and possibly chlorpromazine N-oxide, are neuropharmacologically active.
Serum or plasma
Transfer separated serum or plasma to a plastic transport tube.
Causes for Rejection
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|072132||Chlorpromazine, Serum||3471-0||072132||Chlorpromazine, Serum||ng/mL||3471-0|